Healthcare Services

HER2-Negative Breast Cancer Market: Growth Trends and Forecast to 2030

April 22, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The HER2-Negative Breast Cancer Market Expected To Change From 2026 To 2030?

The her2-negative breast cancer market size has demonstrated robust growth in recent years. It is projected to expand from $17.57 billion in 2025 to $18.95 billion in 2026, at a compound annual growth rate (CAGR) of 7.9%. This historical expansion can be attributed to elements such as increasing breast cancer screening rates, enhanced awareness of hormone receptor-positive cancers, the proliferation of oncology treatment centers, the presence of established chemotherapy protocols, and an increase in clinical oncology research.

The her2-negative breast cancer market is anticipated to show significant expansion over the next few years. It is predicted to reach $25.41 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This projected growth can be attributed to the rising demand for tailored oncology treatments, the increasing adoption of therapies guided by genomics, the expansion of immunotherapy product pipelines, a heightened emphasis on improving progression-free survival, and growing investment in the development of oncology drugs. Notable trends for the forecast period include the increasing uptake of individualized hormone therapy regimens, a rising utilization of cdk4/6 inhibitors, the broadened application of genomic testing for treatment selection, the growing integration of immunotherapy in advanced stages, and an enhanced focus on combination treatment protocols.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

What Primary Drivers Are Shaping The HER2-Negative Breast Cancer Market?

The increasing occurrence of breast cancer cases is projected to stimulate the growth of the HER2-negative breast cancer market going forward. Breast cancer is a condition characterized by the uncontrolled division of abnormal cells in the breast tissue, usually originating in the ducts or lobules. The rising number of breast cancer instances can be attributed to multiple factors, including heightened awareness and improved screening methods, which lead to earlier and more frequent detection. HER2-Negative Breast Cancer plays a critical role in advancing breast cancer research by offering insights into distinct tumor biology and treatment strategies, thereby contributing to the development of more targeted therapies for patients. For instance, in 2025, according to the American Cancer Society, a US-based professional organization company, the United States is anticipated to experience approximately 316,950 new cases of invasive breast cancer in women and 2,800 cases in men, alongside an estimated 59,080 cases of ductal carcinoma in situ (DCIS) diagnosed in women. Therefore, the increasing prevalence of breast cancer cases is driving the expansion of the HER2-negative breast cancer market.

How Are Segments Identified Within The HER2-Negative Breast Cancer Market Segment Framework?

The her2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

What Trends Are Affecting The Growth Of The HER2-Negative Breast Cancer Market?

Leading firms within the HER2-negative breast cancer market are prioritizing the attainment of regulatory clearances to launch novel therapies, broaden their range of products, and strengthen their position in the market. These approvals represent the formal permission given by governmental bodies, enabling companies to commercialize and supply medications or therapies once they have satisfied benchmarks for safety, effectiveness, and quality. As an illustration, in October 2024, Genentech Inc., a biotechnology company based in the US, obtained FDA approval for Itovebi (inavolisib) to be used as a precision therapy for advanced hormone receptor-positive (HR+), HER2-negative breast cancer exhibiting a PIK3CA mutation. This authorization permits Itovebi’s use alongside palbociclib and fulvestrant, substantially extending progression-free survival for patients when contrasted with conventional therapies. This novel treatment approach offers a crucial alternative for individuals with constrained therapeutic options, underscoring the critical role of biomarker testing in pinpointing patients who stand to gain the most from this particular treatment.

Who Are The Companies Competing Within The HER2-Negative Breast Cancer Market?

Major companies operating in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Get The Full HER2-Negative Breast Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

Which Region Is The Leading Market For The HER2-Negative Breast Cancer Market?

North America was the largest region in the HER2-negative breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-negative breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized HER2-Negative Breast Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

Browse Through More Reports Similar to the Global HER2-Negative Breast Cancer Market 2026, By The Business Research Company

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Hr Her2 Breast Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795